gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PTCTHealthcarePharmaceuticals

PTC Therapeutics, Inc. (PTCT)

$68.97+1.25%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$68.97▲ 1.85% in range
Nov 4, 2025Low $59.24 · High $89.55Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

PTC Therapeutics closed at $68.97 on Nov 4, up 1.25%, 23.0% below its 52-week closing high. Volume of 1.3M shares was 1.15× its 20-day average (close to normal).

Split-adjusted performance: +8.3% over one month, +3.6% over six months, +1.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $357.81M, up 69.6% from a year earlier, with a net margin of -14.4%.

Short interest was 8.3M shares at the Oct 15 settlement, down 9.4% from the prior report (10.5% of float, 7.6 days to cover).

Market cap$5.76B83.5M shares
Revenue · quarter$357.8M+69.6% YoY
Diluted EPS$-0.62−410.0% YoY
P/E · TTM—P/S 5.0×
Net margin-14.4%Gross 93.4%
Dividend yieldNone
52-week range59.24 – 89.55−23.0% from high
Volume1.3M1.15× 20-day avg
Volatility · 60d43.5%Annualised
Short % of float10.5%7.6 days to cover
Net cash$1.59BCash $2.13B
Next earnings—Not scheduled
Split-adjusted performance
1W +9.4%1M +8.3%3M −2.7%6M +3.6%YTD −9.2%1Y +1.5%3Y +268.0%5Y +94.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum74
Revenue growth82
Net margin61
Value (low P/E)—
Size91

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short8.3M−9.4% vs prior
Days to cover7.6Settled Oct 15
% of float10.5%
Short vol. 10d47.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PTCTPTC Therapeutics$68.97+1.25%+3.6%+69.6%−14.4%—$5.76B
MANEVeradermics, Incorporated$136.51+2.17%+24.4%———$5.70BCompare
COGTCogent Biosciences$31.49+1.38%−12.2%———$5.46BCompare
MIRMMirum Pharmaceuticals$96.97+11.42%−11.9%+39.6%−22.0%—$6.30BCompare
LGNDLigand Pharmaceuticals$316.13+0.83%+35.9%−31.8%−36.2%122.9$6.32BCompare
ERASErasca$14.91+1.84%+36.8%———$5.21BCompare
IONSIonis Pharmaceuticals$40.15−0.67%−47.8%−40.7%−42.8%—$6.67BCompare
ORKAOruka Therapeutics$101.41+1.87%+45.3%———$6.71BCompare
TVTXTravere Therapeutics$52.42+6.09%+17.1%+36.2%−23.3%—$4.94BCompare

News about PTC Therapeutics

All news →
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research · 6d ago▲ PositiveWhat This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 MillionThe Motley Fool · Jul 13, 2026▲ Positive

Quick answers

What does PTC Therapeutics do?
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.
What is PTCT's market cap?
$5.76B, based on the Nov 4 close of $68.97.
Does PTC Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PTCT is sold short?
8.3M shares, 10.5% of float, as of Oct 15, 2026.
What sector is PTCT in?
Healthcare, in the Pharmaceuticals industry.

About PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

HQ: Warren, NJ991 employeesListed Jun 20, 2013ptcbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology